Frequency Therapeutics said yesterday that it priced its initial public offering at roughly $84 million. The 6-million-share offering priced at $14 per share and includes a 30-day underwriters option on another 900,000 shares that’s worth $12.6 million, the Woburn, Mass.-based company said. Frequency said it expected to begin trading the shares on the NASDAQ exchange […]
Initial Public Offering (IPO)
Frequency Therapeutics registers $100m IPO
Frequency Therapeutics has registered an initial public offering of common stock worth $100 million. Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units. The company applied to the Securities and Exchange Commission have its common stock listed on The Nasdaq Global […]
Livongo share prices double after upsized $356m IPO
Investors added nearly 50% to the share price for Livongo Health (NSDQ:LVGO) today after it raised $355 million with its initial public offering after a last-minute upsizing. The Mountain View, Calif.-based company, which developed a digital health platform to manage chronic diseases, said earlier this week that it planned to float 10.7 million shares at $24 […]
Livongo Health files for $100m IPO
Livongo Health last week filed for an initial public offering worth $100 million for the digital health platform it developed to treat chronic diseases. The Mountain View, Calif.-based company’s initial focus on diabetes involves a smart, cellular-connected glucose meter, automatically-delivered testing materials, real-time coaching and full-time monitoring. The system personalizes messages based on each glucose […]
Livongo preps for $1B IPO
Livongo Health is preparing for a $1 billion initial public offering this year, according to a new report from The Wall Street Journal. The IPO for the Mountain View, Calif.-based diabetes-focused digital health company is set to drop in the third quarter of this year, according to the report. Livongo tapped Morgan Stanley, Goldman Sachs […]
Going public, Provention Bio looks to tackle immune-mediated diseases
Shares in Oldwick, N.J.-based Provention Bio began trading today following the close of its $64 million initial public offering last week. The biopharmaceutical company, lead by co-founder & CEO Ashleigh Palmer, is developing a number of products that aim to prevent or stop the spread of immune-mediated diseases, including Lupus, Crohn’s disease and Type I diabetes. […]
Provention Bio closes $64m IPO
Provention Bio yesterday closed its initial public offering, raising approximately $63.9 million. Funds from the round will help support the Oldwick, N.J.-based company’s clinical-stage biopharmaceuticals that aim to prevent or intercept immune-mediated diseases. Provention Bio said that it expects shares of its common stock will begin trading on Nasdaq under the ticker symbol “PRVB” next […]
Eyenovia looks to $35m IPO for ocular drug-delivery tech
Eyenovia is looking to raise up to $35 million in an initial public offering, according to recent filings. The company plans to use the funds to support trials of its device, which is designed to deliver small doses of drugs to the eye. The New York-based company uses a piezo-electric dispensation technology to deliver microdoses […]
OptiNose IPO pulls in $120m
OptiNose (NSDQ:OPTN) raised $120 million with its initial public offering last week, adding $20 million to the target is set earlier this month. Yardley, Penn.-based OptiNose floated 7.5 million shares at $16 apiece in the offering, above the range it set Oct. 3 for 6.3 million shares at $15 to $17 apiece. The stock, trading on the […]
OptiNose sets terms for $100m IPO
OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC. The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista Capital Partners intend to buy $25 million worth of shares as part of the offering, according to OptiNose. The company […]
